Hybrid Closed‑Loop Automated Insulin Delivery Systems for Adults with Type 1 Diabetes

Recommendation Strength

The American Diabetes Association (ADA) issues a Grade A recommendation—the highest level of evidence—stating that automated insulin delivery (AID) systems should be considered for all adults with type 1 diabetes. 1, 2, 3

In adults with type 1 diabetes, hybrid closed‑loop systems increase time‑in‑range (70–180 mg/dL) substantially compared with sensor‑augmented or conventional pumps. 4, 5, 6, 7, 8
The International Diabetes Closed‑Loop (iDCL) trial showed that hybrid closed‑loop therapy yields a higher percentage of glucose readings within target range, lower mean glucose, and a greater reduction in HbA1c versus sensor‑augmented pump therapy. 4, 5, 6, 7, 8
Conventional continuous subcutaneous insulin infusion (CSII) pumps achieve only a modest HbA1c reduction of ≈0.30 % compared with multiple‑daily‑injection regimens, underscoring the superior efficacy of hybrid closed‑loop control. 4, 5, 6, 7

Hybrid closed‑loop systems significantly lower hypoglycemia exposure, decreasing the low‑blood‑glucose index and time spent below 70 mg/dL, which translates into reduced mortality risk. 4, 5, 6, 7, 8

Automation of basal insulin adjustments reduces treatment burden for patients. 1, 2, 3
Improved glycemic outcomes with hybrid closed‑loop therapy are associated with enhanced quality of life and lower cognitive load, as the system continuously adapts insulin delivery based on real‑time glucose data. 1, 2, 3, 4, 5

The U.S. Food and Drug Administration (FDA) has approved multiple hybrid closed‑loop systems, confirming an acceptable safety profile in clinical trials. 4, 5, 6
Skin irritation from prolonged device wear can occur and should be monitored. 11

All commercially available hybrid closed‑loop systems remain “hybrid”, requiring user input for meal announcements and carbohydrate counting. 4, 5, 9
Patients must be capable of safely operating the device either independently or with caregiver assistance. 1, 2, 3, 10
Aerobic exercise poses a challenge for glucose stability; current systems have limited automated handling of rapid glucose declines during activity. 9

Hybrid closed‑loop therapy provides superior glycemic control compared with sensor‑augmented pump therapy (pump + CGM), primarily due to real‑time automated insulin adjustments. 4, 5, 6, 7, 8
The key differentiator is the system’s ability to continuously modulate insulin delivery based on current glucose readings, a capability absent in conventional pumps. 4, 5

First‑line: Offer hybrid closed‑loop AID to all adults with type 1 diabetes as the preferred insulin delivery method. 1, 2, 10
Capability assessment: Verify that the patient can safely use the device alone or with adequate caregiver support. 1, 2, 3
System selection: Choose a specific hybrid closed‑loop device based on individual circumstances, preferences, and insurance coverage. 10
Alternative pathway: If AID is not feasible, a conventional insulin pump combined with continuous glucose monitoring (sensor‑augmented pump) serves as a second‑line option. 4, 5
CGM integration: Early and continuous use of continuous glucose monitoring is recommended regardless of the insulin delivery method. 1, 2, 3
Access continuity: Patients already using any insulin pump should retain access across insurance payors when transitioning to or from hybrid closed‑loop systems. 10

High‑quality evidence demonstrates that hybrid closed‑loop artificial pancreas systems outperform conventional insulin pumps in time‑in‑range, hypoglycemia reduction, and quality‑of‑life outcomes, supporting their adoption as the first‑choice therapy for adults with type 1 diabetes when technology and resources permit. 1, 2, 3, 10